Harland R N, Barnes D M, Howell A, Ribeiro G G, Taylor J, Sellwood R A
Br J Cancer. 1983 Apr;47(4):511-5. doi: 10.1038/bjc.1983.81.
One hundred and nineteen patients with breast cancer had 2 or more lesions removed for oestrogen (REc) or progesterone receptor (RPc) assay, either synchronously (on 38 occasions) or after an interval (on 91 occasions). In all but 7 both receptors were assayed for each lesion. The assays did not agree on the presence or absence of REc alone, RPc alone or the combination of both receptors in 11, 13 and 16% respectively of the synchronous samples, compared with 23, 30 and 43% of the asynchronous samples. The differences between the synchronous and asynchronous samples were significant for the combined receptors (P = 0.007) but not for REc (P = 0.176) or RPc alone (P = 0.077). Variation between asynchronous biopsies was greater when the earlier lesion contained RPc (18/37 disagreed) than when it did not (8/50) disagreed, P = 0.0023). This was not true for oestrogen receptor. In those remaining receptor positive there was only a weak correlation between the first and second values (Spearman rank correlation coefficient, rho = 0.39 for REc, P less than 0.02, and 0.45 for RPc, 0.05 less than P less than 0.1). Receptor levels and receptor status may change with time. Biopsy is most appropriate at the time when systemic treatment is proposed.
119例乳腺癌患者切除了2个或更多病灶以进行雌激素（REc）或孕激素受体（RPc）检测，检测方式为同步检测（共38次）或间隔一段时间后检测（共91次）。除7例患者外，其余患者对每个病灶均检测了两种受体。对于同步样本，单独REc、单独RPc或两种受体同时存在与否的检测结果不一致的情况分别占11%、13%和16%；而异步样本中这三种情况分别占23%、30%和43%。同步样本和异步样本在联合受体检测结果上差异显著（P = 0.007），但单独REc检测（P = 0.176）和单独RPc检测（P = 0.077）结果差异不显著。当早期病灶含有RPc时，异步活检之间的差异更大（18/37不一致），而早期病灶不含RPc时差异较小（8/50不一致），P = 0.0023）。雌激素受体情况并非如此。在其余受体阳性的患者中，首次和第二次检测值之间只有微弱的相关性（Spearman等级相关系数，REc为rho = 0.39，P < 0.02；RPc为0.45，0.05 < P < 0.1）。受体水平和受体状态可能随时间变化。活检最适合在提议进行全身治疗时进行。
